How AI Is Redefining Indian Pharma for Viksit Bharat 2047

Contents

Executive Summary

This panel discussion explores how artificial intelligence can catalyze India's pharmaceutical industry's transition from volume-based manufacturing to innovation-driven value creation by 2047. The panelists—representing industry leadership, global innovation expertise, AI research, and policy advocacy—discuss concrete near-term applications (regulatory compliance, manufacturing quality, clinical trial support), foundational challenges (data fragmentation, organizational trust, talent gaps), and ecosystem-level solutions required to position India as both a world-class pharmaceutical innovator and a trusted partner in global drug discovery.

Key Takeaways

AI alone is not the solution; trust, ownership, and organizational readiness are the gating factors. Technical capability matters less than leadership commitment to integration, team alignment, and end-to-end workflow transformation.
Manufacturing, regulatory compliance, and clinical trial support are achievable 1–3 year wins that can generate 30–50% productivity gains and create momentum for longer-term R&D innovation. Quick wins fund credibility and capability-building.
India's data asset is vast but dormant. Unlocking fragmented clinical data, post-market surveillance records, diagnostic test repositories, and diagnostic data through partnerships (government, academia, IRO, industry consortia) is the prerequisite for discovery and value innovation. Without this, AI remains theoretical.
Neurosymbolic AI—not black-box generative models—is the required standard for regulated pharma and healthcare. Explainability, alignment with medical guidelines, and grounding in domain knowledge are non-negotiable for doctor trust, regulatory approval, and patient safety.
The IPA-IRO collaboration signals a shift toward ecosystem-level, pre-competitive knowledge infrastructure rather than isolated corporate AI labs. Shared platforms for best practices, regulatory intelligence, and quality knowledge can lift the entire industry and accelerate the pivot from volume to value.

Key Topics Covered

Strategic Shift: From "pharmacy of the world" (20% global generics, 60% vaccines) to a USD 500 billion innovation-led pharma hub
AI Applications Across Value Chain: Discovery, development, manufacturing, clinical trials, regulatory compliance, and patient engagement
Near-Term Use Cases: Documentation automation, manufacturing quality prediction, regulatory submission support, clinical trial workflow optimization
Technical Approaches: Neurosymbolic AI, knowledge graphs, explainability, and trustworthiness in regulated domains
Data Infrastructure Challenges: Fragmentation, siloing, lack of governance, and low adoption rates (e.g., Aadhaar-linked health records: 500M cards but only 5M active usage)
Organizational Barriers: Pilot addiction, lack of ownership, talent gaps in translating AI to domain practice
Government Policy & Ecosystem: Clinical trial harmonization, regulatory reform, data integration, platform-based knowledge sharing
Startup Integration: Pathways for emerging AI companies to collaborate with established pharma
Global Benchmarking: Comparative insights from Eli Lilly's global operations and US market maturity

Key Points & Insights

Data Trust Over Data Quantity: Organizations possess abundant data but suffer from "trust deficit." The core issue is not data shortage but fragmented silos, inconsistency, and lack of single version of truth, preventing teams from acting on AI insights.
Neurosymbolic AI for Regulatory Domains: Explainability and alignment with medical guidelines require moving beyond generative AI blackboxes. Knowledge graphs grounded in domain vocabularies (e.g., DSM-5 for mental health, FDA compliance requirements) enable trustworthy, contextually-aware AI that doctors and regulators can verify.
Pilot-to-Scale Requires Ownership: The "expensive demo" problem—pilots failing due to lack of clear leadership, accountability, and integration into workflows—is a critical organizational barrier, not primarily a technical one. Scaling demands end-to-end strategy, change management, and transparent communication.
Manufacturing Quality as Immediate Opportunity: Predictive analytics for "golden batch" production, root cause analysis from sensor data, and preventive quality management (rather than reactive) offer 30–50% productivity gains and align with both quality and environmental goals in the near term.
Talent Gap in Translation, Not Just AI Engineers: The hardest challenge is finding people who can bridge domain expertise (pharmaceutics, regulatory) and AI capabilities—individuals who understand both the science and the technology and can motivate teams to adopt AI-driven workflows.
Clinical Trials as Strategic Bottleneck: India conducts only 1% of global clinical trials despite holding 17% of global population. Patient enrollment takes 12+ months (vs. 3 months in China). AI-driven workflow optimization and data infrastructure could unlock this USD 500B market opportunity.
Knowledge Graphs as Foundational IP: IRO has developed the world's largest pharma knowledge graph (extracted from millions of documents, last refreshed 2 years ago). Coupled with question-answering and efficacy-toxicology linkage, this enables researchers to compress discovery timelines.
Policy Alignment Accelerating: Government announcements of 1,000 clinical trial centers, deregulation initiatives, and emphasis on biotech R&D allocations show increasing policy support. However, privacy frameworks (Aadhaar/Abha adoption) and data interoperability remain nascent.
Democratization Over Competitive Hoarding: Industry consensus that regulatory intelligence, quality knowledge bases, real-world evidence platforms, and shared data pools should not be duplicated. IPA members can "compete on products but not on infrastructure."
Measurement as Accountability: Implementations must define clear KPIs (time, quality, compliance, cost) and track outcomes. What is not measured is not valued—a critical discipline for moving pilots to enterprise-wide capabilities.

Notable Quotes or Statements

Dr. Amit Shet (IRO): "The central question is not whether AI will transform pharma, but how quickly and deliberately Indian pharma can use AI to shift from the world's largest supplier by volume to its most valuable innovation hub."
Dr. Shahul Patel (Zidus, IPA President): "AI without an owner is like an expensive demo." (on the pilot-to-scale problem)
Dr. Shahul Patel (Zidus): "We compete on products, but we don't need to compete on anything else"—advocating for shared infrastructure and open-access tools.
Vinslow Tucker (Eli Lilly): "AI has to be built on data, and that data has to have governance and a foundation. These centers [global capability centers like Hyderabad] are a great way to establish that in India and export it across the organization."
Mr. Sudaran Jen (IPA Secretary General): "AI is affordable innovation at scale. If we can begin that journey, it will be a big starting point" for India's healthcare ambitions.
Dr. Amit Shet: On neurosymbolic AI: "Terms used are the terms that doctors are trained for"—emphasizing grounding explainability in domain vocabulary, not just pattern recognition.

Speakers & Organizations Mentioned

Entity	Role / Context
Dr. Amit Shet	Founding Director, India AI Research Organization (IRO); Professor, University of South Carolina
Dr. Shahul Patel	Managing Director, Zidus Life Sciences; President, Indian Pharmaceutical Alliance (IPA)
Vinslow Tucker	President & General Manager, Eli Lilly India
Mr. Sudaran Jen	Secretary General, Indian Pharmaceutical Alliance
Priyanka (Moderator)	Topic: Volume-to-value transition in Indian pharma
Indian Pharmaceutical Alliance (IPA)	Industry advocacy body; 23+ member companies; focal point for collaborative AI initiatives
India AI Research Organization (IRO)	Newly founded research org; government PPP model; identified pharma as flagship sector
Eli Lilly	Global pharma; recently opened Capability Center in Hyderabad; trillion-dollar market cap
Zidus Life Sciences	Indian pharma with focus on small molecules, biologics, vaccines; global markets
BCG	Knowledge partner for IPA-IRO collaboration
Dr. Honavar	IRO affiliate; expertise in diffusion models and molecular design
Dr. Shinas Parasa Sadhi	IRO affiliate; original work in drug development and small molecule design
Dr. Nyogi	University of Texas Austin; IRO faculty
Dr. Wasan Hana	Penn State; IRO faculty
Dr. Sini Parthasati	Ohio State; IRO faculty
Serum Institute	Mentioned for OCR quality improvements in regional languages
Government of India	Union Budget (biotech/pharma allocations); deregulation committee (Chairman: Rajiv Kaba); Health Ministry announcements on AI in healthcare and open data systems
Aadhaar/Abha	Digital health ID systems; noted gap: 1.4B Aadhaar holders, 500M Abha users, but only 5M active usage

Technical Concepts & Resources

Concept / Tool	Context
Neurosymbolic AI	Hybrid approach combining neural networks (learn patterns from data) with symbolic knowledge (domain rules, ontologies, guidelines). Enables explainability and alignment required in pharma/healthcare.
Knowledge Graphs	Structured semantic representation of domain knowledge extracted from literature. IRO has world's largest pharma knowledge graph; used for question-answering, efficacy-toxicology linkage, regulatory compliance.
Large Language Models (LLMs) / Generative AI	Acknowledged as "blackbox" for regulated domains without grounding. Risk of hallucination, misalignment with medical guidelines. Require neurosymbolic wrapping for trustworthiness.
Diffusion Models	Enabled by knowledge graphs; applicable to molecular design and small molecule discovery (near-term, 1–2 year horizon).
OCR (Optical Character Recognition)	Improving across multiple languages; enables digitization of legacy pharma data.
Explainability / Interpretability	Critical requirement: AI decisions must be explainable to domain experts (doctors, regulators) using domain vocabulary (e.g., "edema" not "water retention").
Clinical Trial Workflow AI	Applications: patient enrollment optimization, data quality assurance, FDA compliance checks, adverse event detection.
Manufacturing Quality Prediction	Sensor-driven predictive analytics for batch outcomes; root cause analysis; preventive replanning. Targets 30–50% productivity gain.
Regulatory Compliance Automation	Knowledge graph + NLP for converting regulatory documents into structured representations; automated form-filling and validation.
Post-Market Surveillance / Pharmacovigilance Data	Underutilized real-world evidence asset for discovery and safety monitoring.
Phase 3 & Phase 4 Clinical Data	Data captured by pharma companies and regulators; fragmented but available for aggregation and AI-driven insights.
DSM-5 (Diagnostic and Statistical Manual)	Domain ontology used in mental health AI projects to ensure contextually appropriate AI responses (e.g., avoiding suicidality triggers in MDD conversations).
FDA Guidelines	Referenced as alignment target for neurosymbolic AI systems in clinical decision support.
Aadhaar / Abha Health Records	Government digital ID and health record systems; low adoption (5M of 500M potential) but strategic for future data integration.
Platform as a Service (PaaS)	IPA initiative to create shared AI platforms for regulatory intelligence, quality knowledge bases, real-world evidence pools.

Additional Observations

Global Context: Eli Lilly's Hyderabad GCC and 1 trillion USD market cap serve as benchmarks. US pharma companies benefit from data infrastructure, connectivity, and regulatory clarity that India is still building.
Policy Momentum: First-time government emphasis on pharma R&D and biotech in union budget; deregulation committee active; clinical trial infrastructure expansion underway. However, implementation timelines are 2–5 years for IC harmonization and regulatory alignment.
Startup Ecosystem Gap: Early-stage AI companies struggle to partner with large pharma due to resource constraints and evaluation bottlenecks. Proposed solution: IPA-managed portal/platform for lead evaluation and syndication.
Patient Impact as North Star: Across all discussion, recurring theme is that innovation must translate to improved patient outcomes and affordability. Without this, AI adoption is hollow.